Abstract
Résumé
Type 2 Diabetes Mellitus and Hypertension

Macrovascular Disease
Clinical features
Pathophysiological features
Microvascular Disease
Clinical features
Pathophysiological features
Mechanisms of Vascular Complications in Diabetes and the Impact of Hypertension

AGE-RAGE axis
Oxidative stress and Nox
Inflammation and the immune system
Guzik TJ, Cosentino F. Epigenetics and immunometabolism in diabetes and aging [e-pub ahead of print]. Antiox Redox Signal https://doi.org/10.1089/ars.2017.7299.
Guzik TJ, Cosentino F. Epigenetics and immunometabolism in diabetes and aging [e-pub ahead of print]. Antiox Redox Signal https://doi.org/10.1089/ars.2017.7299.
Genetic evidence
Clinical evidence
Guzik TJ, Cosentino F. Epigenetics and immunometabolism in diabetes and aging [e-pub ahead of print]. Antiox Redox Signal https://doi.org/10.1089/ars.2017.7299.
Anti-inflammatory properties of antidiabetic therapies
Guzik TJ, Cosentino F. Epigenetics and immunometabolism in diabetes and aging [e-pub ahead of print]. Antiox Redox Signal https://doi.org/10.1089/ars.2017.7299.
MiRNAs, Diabetes, and Vascular Complications
Treatment of diabetes mellitus and its cardiovascular complications
Diabetes, vasoprotection, and potential new therapies
Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines [e-pub ahead of print]. J Am Coll Cardiol https://doi.org/10.1016/j.jacc.2017.11.006.
Conclusions
Funding Sources
Disclosures
References
- IDF Diabetes Atlas: Global estimates for the prevalence of diabetes for 2015 and 2040.Diabetes Res Clin Pract. 2017; 128: 40-50
- Global disparities of hypertension prevalence and control: a systematic analysis of population-based studies from 90 countries.Circulation. 2016; 134: 441-450
- Risk factors for cardiovascular mortality in Mexican Americans and non-Hispanic whites. San Antonio Heart Study.Am J Epidemiol. 1990; 131: 423-433
- Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus.Diabetes. 2009; 58: 773-795
- The effect of insulin on renal handling of sodium, potassium, calcium, and phosphate in man.J Clin Invest. 1975; 55: 845-855
- β-cell function in type 2 diabetes.Metabolism. 2014; 63: 1217-1227
- Obesity and its metabolic complications: the role of adipokines and the relationship between obesity, inflammation, insulin resistance, dyslipidemia and nonalcoholic fatty liver disease.Int J Mol Sci. 2014; 15: 6184-6223
- The pathobiology of diabetic complications: a unifying mechanism.Diabetes. 2005; 54: 1615-1625
- Emerging roles for microRNAs in diabetic microvascular disease: novel targets for therapy.Endocr Rev. 2017; 38: 145-168
- Oxidative stress in atherosclerosis.Curr Atheroscler Rep. 2017; 19: 42
- Type 2 diabetes as a “coronary heart disease equivalent”: an 18-year prospective population-based study in Finnish subjects.Diabetes Care. 2005; 28: 2901-2907
- Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction.N Engl J Med. 1998; 339: 229-234
- The impact of diabetes on survival following myocardial infarction in men vs women. The Framingham Study.JAMA. 1988; 260: 3456-3460
- Risk factors for early death in non-insulin dependent diabetes and men with known glucose tolerance status.BMJ. 1993; 307: 295-299
- Effects of randomization to intensive glucose control on adverse events, cardiovascular disease, and mortality in older versus younger adults in the ACCORD trial.Diabetes Care. 2014; 37: 634-643
- Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial.Diabetologia. 2016; 59: 2298-2307
- Insulin resistance in essential hypertension.N Engl J Med. 1987; 317: 350-357
- Obese adipocytes show ultrastructural features of stressed cells and die of pyroptosis.J Lipid Res. 2013; 54: 2423-2436
- ‘Dysfunctional’ adipose tissue in cardiovascular disease: a reprogrammable target or an innocent bystander?.Cardiovasc Res. 2017; 113: 997-998
- Muscle and adipose tissue morphology, insulin sensitivity and beta-cell function in diabetic and nondiabetic obese patients: effects of bariatric surgery.Sci Rep. 2017; 7: 9007
- Endothelial dysfunction in impaired fasting glycemia, impaired glucose tolerance, and type 2 diabetes mellitus.Am J Cardiol. 2008; 102: 497-498
- Endothelial function and arterial stiffness in normotensive normoglycemic first-degree relatives of diabetic patients are independent of the metabolic syndrome.Nutr Metab Cardiovasc Dis. 2008; 18: 349-356
- Endothelial nitric oxide production and insulin sensitivity. A physiological link with implications for pathogenesis of cardiovascular disease.Circulation. 1996; 93: 1331-1333
- Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I.Circulation. 2003; 108: 1527-1532
- Endothelial dysfunction and atherothrombosis in mild hyperhomocysteinemia.Vasc Med. 2002; 7: 227-239
- Insulin-induced microvascular recruitment in skin and muscle are related and both are associated with whole-body glucose uptake.Microcirculation. 2012; 19: 494-500
- Vascular inflammation and endothelial dysfunction in experimental hypertension.Int J Hypertens. 2011; : 281240
- Vascular biology of ageing-Implications in hypertension.J Mol Cell Cardiol. 2015; 83: 112-121
- Oxidative stress, inflammation, and vascular aging in hypertension.Hypertension. 2017; 70: 660-667
- Accelerated vascular aging as a paradigm for hypertensive vascular disease: prevention and therapy.Can J Cardiol. 2016; 32: 680-686
- Cellular senescence and vascular disease: novel routes to better understanding and therapy.Can J Cardiol. 2016; 32: 612-623
- Mechanisms, pathophysiology, and therapy of arterial stiffness.Arterioscler Thromb Vasc Biol. 2005; 25: 932-943
- Prevalence of diabetic retinopathy in the United States, 2005-2008.JAMA. 2010; 304: 649-656
- Diabetic retinopathy.Diabetes Care. 2004; 27: 2540-2553
- Prevalence of diabetic retinopathy in type 2 diabetes in developing and developed countries.Diabet Med. 2013; 30: 387-398
- Clinical characteristics, complications, comorbidities and treatment patterns among patients with type 2 diabetes mellitus in a large integrated health system.BMJ Open Diabetes Res Care. 2015; 3: e000093
- Comparative effects of microvascular and macrovascular disease on the risk of major outcomes in patients with type 2 diabetes.Cardiovasc Diabetol. 2017; 16: 95
- Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial.Lancet. 2008; 372: 1385-1393
- Diabetic microangiopathy: pathogenetic insights and novel therapeutic approaches.Vascul Pharmacol. 2017; 90: 1-7
- Advanced glycation end products (AGE) and diabetes: cause, effect, or both?.Curr Diab Rep. 2014; 14: 453
- Methylglyoxal-glyoxalase 1 balance: the root of vascular damage.Int J Mol Sci. 2017; 18: 188-202
- Unlocking the biology of RAGE in diabetic microvascular complications.Trends Endocrinol Metab. 2014; 25: 15-22
- Linking RAGE and Nox in diabetic micro- and macrovascular complications.Diabetes Metab. 2015; 41: 272-281
- Kidney, heart and brain: three organs targeted by ageing and glycation.Clin Sci (Lond). 2017; 131: 1069-1092
- 2016 ATVB Plenary Lecture: receptor for advanced glycation endproducts and implications for the pathogenesis an treatment of cardiometabolic disorders: spotlight on the macrophage.Arterioscler Thromb Vasc Biol. 2017; 37: 613-621
- Pharmacologic approaches against advanced glycation end products (AGEs) in diabetic cardiovascular disease.Res Cardiovasc Med. 2015; 4: e26949
- Improved arterial compliance by a novel advanced glycation end-product crosslink breaker.Circulation. 2001; 104: 1464-1470
- Mechanisms of increased vascular superoxide production in human diabetes mellitus: role of NAD(P)H oxidase and endothelial nitric oxide synthase.Circulation. 2002; 105: 1656-1662
- Diabetes and complications: cellular signaling pathways, current understanding and targeted therapies.Curr Drug Targets. 2016; 17: 1309-1328
- Oxidative stress, Nox isoforms and complications of diabetes-potential targets for novel therapies.J Cardiovasc Transl Res. 2012; 5: 509-518
- Molecular mechanisms of ROS production and oxidative stress in diabetes.Biochem J. 2016; 473: 4527-4550
- NADPH oxidase 1 plays a key role in diabetes mellitus accelerated atherosclerosis.Circulation. 2013; 127: 1888-1902
- Reactive oxygen species can provide atheroprotection via NOX4-dependent inhibition of inflammation and vascular remodeling.Arterioscler Thromb Vasc Biol. 2016; 36: 295-307
- Genetic targeting or pharmacologic inhibition of NADPH oxidase nox4 provides renoprotection in long-term diabetic nephropathy.J Am Soc Nephrol. 2014; 25: 1237-1254
- Renoprotective effects of a novel Nox1/4 inhibitor in a mouse model of Type 2 diabetes.Clin Sci (Lond). 2013; 124: 191-202
- Nephropathy and elevated BP in mice with podocyte-specific NADPH oxidase 5 expression.J Am Soc Nephrol. 2014; 25: 784-797
- NADPH oxidase Nox5 accelerates renal injury in diabetic nephropathy.Diabetes. 2017; 66: 2691-2703
- Targeting select cellular stress pathways to prevent hyperglycemia-related complications: shifting the paradigm.Drugs. 2016; 76: 1081-1091
Guzik TJ, Cosentino F. Epigenetics and immunometabolism in diabetes and aging [e-pub ahead of print]. Antiox Redox Signal https://doi.org/10.1089/ars.2017.7299.
- Sphingosine-1-phosphate signalling-a key player in the pathogenesis of angiotensin II-induced hypertension.Cardiovasc Res. 2017; 113: 123-133
- Differential white cell count and incident type 2 diabetes: the Insulin Resistance Atherosclerosis Study.Diabetologia. 2014; 57: 83-92
- Integrative miRNA and whole-genome analyses of epicardial adipose tissue in patients with coronary atherosclerosis.Cardiovasc Res. 2016; 109: 228-239
- The role of inflammatory biomarkers in developing targeted cardiovascular therapies: lessons from the cardiovascular inflammation reduction trials.Cardiovasc Res. 2016; 109: 9-23
- Targeting inflammation in the treatment of type 2 diabetes: time to start.Nat Rev Drug Discov. 2014; 13: 465-476
- Interleukin-1 (IL-1) family of cytokines: role in type 2 diabetes.Clin Chim Acta. 2012; 413: 1163-1170
- Level of serum IL-12 and its correlation with endothelial dysfunction, insulin resistance, proinflammatory cytokines and lipid profile in newly diagnosed type 2 diabetes.Diabetes Res Clin Pract. 2011; 94: 255-261
- The implication of proinflammatory cytokines in type 2 diabetes.Front Biosci. 2008; 13: 5187-5194
- Glycemic control in diabetes is restored by therapeutic manipulation of cytokines that regulate beta cell stress.Nat Med. 2014; 20: 1417-1426
- Circulating pro-inflammatory cytokines and adiponectin in young men with type 2 diabetes.Acta Diabetol. 2011; 48: 113-119
- Inflammation and metabolic cardiomyopathy.Cardiovasc Res. 2017; 113: 389-398
- An overview of the inflammatory signalling mechanisms in the myocardium underlying the development of diabetic cardiomyopathy.Cardiovasc Res. 2017; 113: 378-388
- An interaction map of circulating metabolites, immune gene networks, and their genetic regulation.Genome Biol. 2017; 18: 146
- The metabochip, a custom genotyping array for genetic studies of metabolic, cardiovascular, and anthropometric traits.PLoS Genet. 2012; 8: e1002793
- Inflammation, metaflammation and immunometabolic disorders.Nature. 2017; 542: 177-185
- Effects of genetic loci associated with central obesity on adipocyte lipolysis.PLoS One. 2016; 11: e0153990
- Partitioning the heritability of coronary artery disease highlights the importance of immune-mediated processes and epigenetic sites associated with transcriptional activity.Cardiovasc Res. 2017; 113: 973-983
- The role of infiltrating immune cells in dysfunctional adipose tissue.Cardiovasc Res. 2017; 113: 1009-1023
- Antiinflammatory therapy with canakinumab for atherosclerotic disease.N Engl J Med. 2017; 377: 1119-1131
- Double-blind, randomized study evaluating the glycemic and anti-inflammatory effects of subcutaneous LY2189102, a neutralizing IL-1beta antibody, in patients with type 2 diabetes.Diabetes Care. 2013; 36: 2239-2246
- Metformin improves obesity-associated inflammation by altering macrophages polarization.Mol Cell Endocrinol. 2018; 461: 256-264
- The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta.Nature. 1998; 396: 77-80
- Treatment with high dose salicylates improves cardiometabolic parameters: meta-analysis of randomized controlled trials.Metabolism. 2017; 71: 94-106
- Targeting inflammation in diabetes: newer therapeutic options.World J Diabetes. 2014; 5: 697-710
- Oral histone deacetylase inhibitor synergises with T cell targeted immunotherapy to preserve beta cell metabolic function and induce stable remission of new-onset autoimmune diabetes in NOD mice.Diabetologia. 2018; 61: 389-398
- Histone deacetylase (HDAC) inhibition as a novel treatment for diabetes mellitus.Mol Med. 2011; 17: 378-390
- SirT1 regulates adipose tissue inflammation.Diabetes. 2011; 60: 3235-3245
- Role of microRNAs in type 2 diabetes and associated vascular complications.Biochimie. 2017; 139: 9-19
- Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes.Eur Heart J. 2015; 36: 2288-2296
- Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study.BMJ. 2000; 321: 412-419
- Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38.BMJ. 1998; 317: 706-713
- Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes.N Engl J Med. 2015; 373: 2117-2128
- Liraglutide and cardiovascular outcomes in type 2 diabetes.N Engl J Med. 2016; 375: 311-322
- Restoring normoglycaemia by use of a very low calorie diet in long- and short-duration Type 2 diabetes.Diabet Med. 2015; 32: 1149-1155
- Bariatric surgery versus conventional medical treatment in obese patients with type 2 diabetes: 5 year follow-up of an open-label, single-centre, randomised controlled trial.Lancet. 2015; 386: 964-973
- Weight loss decreases excess pancreatic triacylglycerol specifically in type 2 diabetes.Diabetes Care. 2016; 39: 158-165
- The mechanisms of action of metformin.Diabetologia. 2017; 60: 1577-1585
- Long-term effects of metformin on endothelial function in type 2 diabetes: a randomized controlled trial.J Intern Med. 2014; 275: 59-70
- Effects of short-term treatment with metformin on markers of endothelial function and inflammatory activity in type 2 diabetes mellitus: a randomized, placebo-controlled trial.J Intern Med. 2005; 257: 100-109
- Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34).Lancet. 1998; 352: 854-865
- Inflammation in diabetes mellitus: role of peroxisome proliferator-activated receptor-alpha and peroxisome proliferator-activated receptor-gamma agonists.Am J Cardiol. 2007; 99: 27B-40B
- Pioglitazone treatment reduces adipose tissue inflammation through reduction of mast cell and macrophage number and by improving vascularity.PLoS One. 2014; 9: e102190
- Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial.Lancet. 2005; 366: 1279-1289
- The cardiovascular safety of incretin-based therapies: a review of the evidence.Cardiovasc Diabetol. 2013; 12: 130
- The cardiovascular biology of glucagon-like peptide-1.Cell Metab. 2016; 24: 15-30
- Effects of liraglutide on cardiovascular risk biomarkers in patients with type 2 diabetes and albuminuria: a sub-analysis of a randomized, placebo-controlled, double-blind, crossover trial.Diabetes Obes Metab. 2017; 19: 901-905
- Sodium-glucose co-transporters and their inhibition: clinical physiology.Cell Metab. 2017; 26: 27-38
- CV protection in the EMPA-REG OUTCOME trial: a “thrifty substrate” hypothesis.Diabetes Care. 2016; 39: 1108-1114
- The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats.Redox Biol. 2017; 13: 370-385
- Is glucose control important for prevention of cardiovascular disease in diabetes?.Diabetes Care. 2013; 36: S259-S263
- Drug treatment of hypertension: focus on vascular health.Drugs. 2016; 76: 1529-1550
Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines [e-pub ahead of print]. J Am Coll Cardiol https://doi.org/10.1016/j.jacc.2017.11.006.
- Hypertension Canada's 2017 Guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults.Can J Cardiol. 2017; 33: 557-576
- Characterization of the potent, selective Nrf2 activator, 3-(pyridin-3-ylsulfonyl)-5-(trifluoromethyl)-2h-chromen-2-one, in cellular and in vivo models of pulmonary oxidative stress.J Pharmacol Exp Ther. 2017; 363: 114-125
- The nuclear factor (erythroid-derived 2)-like 2 (Nrf2) activator dh404 protects against diabetes-induced endothelial dysfunction.Cardiovasc Diabetol. 2017; 16: 33
- DPP-4 inhibition by linagliptin attenuates obesity-related inflammation and insulin resistance by regulating M1/M2 macrophage polarization.Diabetes. 2016; 65: 2966-2979
- Therapies on the horizon for diabetic kidney disease.Curr Diab Rep. 2015; 15: 111
- Nanotherapeutics for inhibition of atherogenesis and modulation of inflammation in atherosclerotic plaques.Cardiovasc Res. 2016; 109: 283-293
Article Info
Publication History
Footnotes
See page 581 for disclosure information.
Identification
Copyright
User License
Creative Commons Attribution (CC BY 4.0) |
Permitted
- Read, print & download
- Redistribute or republish the final article
- Text & data mine
- Translate the article
- Reuse portions or extracts from the article in other works
- Sell or re-use for commercial purposes
Elsevier's open access license policy